Prenetics operates through two main segments: a Diagnostics segment focused on precision oncology testing services, and a Prevention segment engaged in genetics testing and stool-based DNA tests for early colorectal cancer screening. The company has diversified its revenue streams beyond traditional diagnostics through high-growth consumer health brands while maintaining its core cancer-focused diagnostic capabilities.
Cyborg Score Rationale
Prenetics demonstrates strong momentum driven by IM8's exceptional growth trajectory and strategic celebrity partnerships. However, profitability remains a challenge—the company struggled historically to turn profits post-listing. Recent Q1 2026 revenue of $36M indicates solid revenue generation, but execution risks remain around scaling the supplement business while maintaining diagnostics operations.
Top Insights
(May 2026) IM8 achieved $100M+ annual recurring revenue within 11 months of launch, fastest growth trajectory ever recorded in supplement industry history
(May 2026) Q1 2026 preliminary revenue reported at $36M; company reporting strong operational momentum across multiple business segments
Dual business model combining B2C supplement brand with established B2B precision diagnostics creates defensive revenue streams and cross-selling opportunities
Strategic partnerships with world-class athletes (David Beckham co-founder, Aryna Sabalenka endorser) provide authentic brand positioning and global distribution leverage
Named Competitors
Invitae — Clinical genetic testing and diagnostics
Myriad Genetics — Molecular diagnostics and genetic testing
Guardant Health — Cancer-focused liquid biopsy diagnostics
GNC — Health supplement retail and DTC
Recent Developments
(May 2026) IM8 announced multi-year partnership with NBA champion Giannis Antetokounmpo as global brand ambassador